Contineum Therapeutics (CTNM) Equity Ratio: 2023-2025
Historic Equity Ratio for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to 0.95.
- Contineum Therapeutics' Equity Ratio fell 2.83% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year decrease of 2.83%. This contributed to the annual value of 0.93 for FY2024, which is 278.60% up from last year.
- Per Contineum Therapeutics' latest filing, its Equity Ratio stood at 0.95 for Q3 2025, which was up 0.91% from 0.94 recorded in Q2 2025.
- Contineum Therapeutics' Equity Ratio's 5-year high stood at 0.98 during Q2 2024, with a 5-year trough of -0.61 in Q1 2024.
- Its 3-year average for Equity Ratio is 0.57, with a median of 0.93 in 2025.
- As far as peak fluctuations go, Contineum Therapeutics' Equity Ratio surged by 278.60% in 2024, and later decreased by 4.63% in 2025.
- Contineum Therapeutics' Equity Ratio (Quarterly) stood at -0.52 in 2023, then surged by 278.60% to 0.93 in 2024, then dropped by 2.83% to 0.95 in 2025.
- Its Equity Ratio was 0.95 in Q3 2025, compared to 0.94 in Q2 2025 and 0.93 in Q1 2025.